Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

IBD after liver transplantation for primary sclerosing cholangitis

This month's issue of the American Journal of Gastroenterology investigates the course of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.

News image

Inflammatory bowel disease (IBD) after liver transplantation for primary sclerosing cholangitis (PSC) is complex, with several IBD-, primary sclerosing cholangitis-, and transplant-related factors interplaying with each other.

Dr Jayant Talwalkar and colleagues from Minnesota, USA reviewed the course of IBD after liver transplantation in these patients.

The team report that approximately one-third of patients with known IBD improve, and one-third paradoxically worsen, after liver transplantation for primary sclerosing cholangitis.

Active IBD, discontinuation of 5-aminosalicylates (5-ASA) at time of liver transplantation and tacrolimus-based immunosuppression may be associated with an unfavorable course of IBD after liver transplantation.

The team found that about 1430% patients with primary sclerosing cholangitis may develop de novo IBD 10 years after liver transplantation.

Liver transplantation confers a high risk of pouchitis after ileal pouch-anal anastomosis, although it may not be higher than baseline rates for primary sclerosing cholangitis patients.

The team noted that the risk of colorectal cancer continues to be high after liver transplantation for primary sclerosing cholangitis, and is higher in this cohort of patients with primary sclerosing cholangitis-IBD, compared with patients undergoing liver transplantation for other indications.

IBD does not adversely affect patient survival after liver transplantation, although the risk of recurrent primary sclerosing cholangitis in the allograft may be higher in patients with IBD and an intact colon at time of liver transplantation.

The researchers report that standard therapy with 5-ASA and/or azathioprine may be appropriate for treatment of active IBD after liver transplantation and maintenance of remission.

Dr Talwalkar's team concludes, "Anti-tumor necrosis factor-α agents are effective, but should be used with caution because of high risk of adverse events."

"The management of IBD after liver transplantation requires close coordination between transplant hepatologists and IBD experts."

Am J Gastroenterol 2013; 108: 14171425
26 September 2013

Go to top of page Email this page Email this page to a colleague

 07 May 2015

Advanced search
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Menarche and NAFLD
 04 May 2015 
Endoscope storage and microbial colonization
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
CRP and acute diverticulitis
 13 April 2015 
Immune based treatments for HCC
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Nonceliac gluten sensitivity
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us